Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Gets Imfinzi Boost From CASPIAN Lung Cancer Trial

Executive Summary

Prospects for AstraZeneca’s PD-L1 inhibitor Imfinzi received a welcome boost from an interim analysis of the Phase III study in first-line small-cell lung cancer.

You may also be interested in...



AstraZeneca Q2 Preview: Cancer Drug Trio To Keep Growing

Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.

BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451

BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.

Mystic Miss Not Make Or Break For Imfinzi

While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is not going to have much of an effect on the potential for the company which has carved out a sizeable niche for the drug in stage III NSCLC.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel